Fundz

Xeltis raises an additional €20.5m to advance aXess™ toward FDA approval and US commercial launch with Horizon 3 Healthcare as the lead investor.

PRIVATEJul 28, 2026

Amount Raised

€20.5 Million

Round Type

Venture

EindhovenManufacturingBiotechnologyHealth Care

Investors

DaVitaHorizon 3 HealthcareEQT Life SciencesVi PartnersInvest NlEuropean Innovation Council

Description

Xeltis announced it raised an additional €20.5m from new and existing shareholders to fund the ongoing US pivotal trial of aXess™, its pioneering living vascular access solution. The funding will also facilitate the FDA submission and commercial rollout in Europe. The company aims to enhance its manufacturing capabilities and continue the advancement of its clinical programs. This financing demonstrates robust investor confidence in Xeltis' strategy.

Who to call at Xeltis, and when

A new round usually means Xeltis is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Xeltis raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Xeltis, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Xeltis

Location

Eindhoven, North Brabant, Netherlands

About

Xeltis is a medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels. The Company seeks to address the limitations of currently available options for the millions of people requiring hemodialysis access grafts or cardiovascular replacements every year. Xeltis' proprietary endogenous tissue restoration (ETR) platform utilizes an advanced polymer implant which regenerates the patient's own tissue before gradually being absorbed and leaving new, living, and long-lasting vessels in place.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Xeltis raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsEliane S., Chief Executive Officer hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Xeltis's next move

See what Strategic adds

Xeltis raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.